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ABSTRACT 
 
Aim of the study: 
The aim of the study is to assess the incidence of hormone receptor 
positivity in females with carcinoma breast in relation to its clinical and 
pathological characteristics and thereby predicting the tumor response to 
endocrine therapy and to formulate the adjuvant treatment modality. 
Materials and Methods: 
 The study sample included 75 female patients with carcinoma breast. They 
were selected from the general surgical wards of Tirunelveli medical college 
hospital and thye study was done for a period of  18 months.  
Biopsy samples (either Trucut biopsy or postop mastectomy specimes) 
were sent to pathology lab where they were processed and analysed for the  
histological subtype of the tumor, its pathological grading and the clearance of 
resected margins of the tumor. 
 Hormonal receptor assay was done using Immunohistochemistry technique 
in our college pathology department and results were interpreted. 
Inclusion criteria: 
1. Clinically diagnosed breast malignancy in females of all age groups 
2. Age of patient, tumor size, histological subtype and grading of the 
tumor 
3. Trucut biopsy and mastectomy specimens 
 
Exclusion criteria: 
1. Patients already treated for contralateral breast carcinoma 
2. Male breast carcinoma 
Results: 
 In my study a total of 75 female patients with breast cancer in my institute 
were studied. the incidence of ER, PR, Her2 neu receptors among them 
correlating with age, tumor size, histological type and the pathological grading 
was evaluated. 52 patients (69.33%) were positive for estrogen receptor and 23 
(30.66%)  were negative. 39 patients (52%) were progesterone receptor positive 
and 36 (48%) were progesterone receptor negative. 28 (37.33%) patients had Her2 
receptor positive and 47 (62.66%) were negative. Most of the tumors in women 
above45 years of age were hormone receptor positive. In women younger than 45 
years both positive and negative were nearly equal. 
Conclusion: 
 These results were comparable with the previous studies and thus reinforce 
the usefulness of estimation of the receptor status for treatment purpose in breast 
carcinoma. The patients with hormone receptor positivity in my study received 
endocrine therapy with tamoxifen. 
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Introduction 
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INTRODUCTION 
 
Breast cancer is the most common cancer among women. Worldwide over 
1.1 million women are diagnosed with this disease each year and incidence rates 
are still on the increase in several countries. Breast cancer is more common in 
elderly women. According to literature breast cancer occurring in younger women 
are of more aggressive type. 
They are usually, 
- High grade 
- Poorly differentiated 
- High tumor invasive potential 
- Greater chances of early lymphatic spread 
- ER,PR negative, Her2 positive  
Recurrence of the tumor is more common in younger women compared to 
elderly women. 
Clinically, in young age, breast tumors are of large size, with greater 
lymphatic spread. 
The most important prognostic factor is lymph node status(N) and next to it 
is the tumor size(T). 
 The final outcome in breast cancer management depends upon the initial 
stage of the tumor at diagnosis and associated prognostic factors such as status of 
the  lymph nodes, size of the tumor and grading of the tumor. 
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Therefore it is essential to find the markers that have predictive and 
prognostic values. It predicts the chances of recurrence of cancer and also 
identifies which patients do and which do not benefit from adjuvant treatment. 
So, patients with low-risk are avoided of unnecessary adjuvant treatment. 
And also the patients with high risk could be identified and given appropriate, 
early and aggressive treatment. 
Estrogen and progesterone receptors (ER, PR) and more recently, HER- 
2/neu have with increasing importance influenced the management of the 
malignancy. Immunohistochemical (IHC) detection has become essential to many 
malignancies and plays a key role in tumor diagnosis, treatment and prognostic 
assessment. 
In this study, we studied 75 cases of breast cancer patients, to detect the 
expression of estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor-2 (HER2), by IHC and analyzed the associations 
between these indicators and the clinico- pathological characteristics. 
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AIM OF STUDY 
 
 To assess the incidence of hormone receptor positivity in females with 
carcinoma breast. 
 
OBJECTIVES OF THE STUDY: 
1. To identify hormonal receptor status in female patients with breast 
malignancies 
2. To  predict the tumor response to endocrine therapy 
3. To compare hormonal receptor status with clinicopathological grading 
of the tumor 
4. To formulate the adjuvant treatment modality 
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MATERIALS AND METHODS 
 
 A study of  cases of carcinoma breast in females were done. Sample 
included 75 patients. Patients  for clinical study were selected from the general 
surgical wards of Tirunelveli medical college hospital for a period of  18 months. 
The study subjects were selected when they presented with the following 
inclusion and exclusion criteria. 
 
Inclusion criteria: 
1. Clinically diagnosed breast malignancy in females of all age groups 
2. Age of patient, tumor size, histological subtype and grading of the 
tumor 
3. Trucut biopsy and mastectomy specimens 
 
Exclusion criteria: 
1. Patients already treated for contralateral breast carcinoma 
2. Male breast carcinoma 
 
 
 
  5 
 
Method used: 
 Biopsy samples (either Trucut biopsy or post-op mastectomy specimens) 
were sent to pathology lab where they were processed and analysed for the  
histological subtype of the tumor, its pathological grading and the clearance of 
resected margins of the tumor. 
 Hormonal receptor assay was done using Immunohistochemistry technique 
in our college pathology department and results were interpreted. 
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REVIEW OF LITERATURE 
 
 Carcinoma breast is more common in developed, western countries. It is 
the second most common cancer in females. Incidence is 19-34%. Median age of 
onset is 47 years. Malignancy in one breast increases the risk of developing 
malignancy in the other breast by 3 – 4 times. It can be familial in 2- 5% patients. 
Anatomy of the breast: 
1. The breast  is a modified sweat gland derived from the 
ectodermal milk lines bilaterally in 7th week of intrauterine life. 
2. It is an accessory reproductive organ. 
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Situation: 
The breast lies in the superficial to the fascia. 
Axillary tail of Spence- extension of the breast that passes through the 
foramen of Langer and therefore this part of breast is deep to the fascia. 
Significance: 1. Proximity to anterior group of axillary nodes. So 
malignancy in tail of breast may be mistaken for lymph node enlargement. 
Extent: 
 Vertically-  Second to the sixth rib 
Horizontally-  mid-axillary line to the lateral border of the sternum 
Deep relations: 
1. Muscles deep to breast-  
pectoralis major 
serrartus anterior 
external oblique of the abdomen. 
2. Separated from deep fascia by loose areolar tissue. 
Structure of the breast: Breast is a glandular tissue embedded in fibrofatty 
stroma. 
The skin: Nipple - A conical projection present at the level of fourth 
intercostal space. 15 to 20 lactiferous ducts pierce the nipple. It contains circular 
and longitudinal smooth muscle fibres that makes the nipple to contract. 
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Areola- skin surrounding the nipple base and is pigmented 
The parenchyma:  
• -Made of glandular tissue containing 15 to 20 lobes. 
• -Each lobe is made up of group of alveoli and it is drained by 
lactiferous duct.  
• -Each duct has a dilatation at its termination - lactiferous sinus 
beneath the nipple. 
• -Primary secretory unit - group of alveoli draining into duct. 
• -Myoepithelium surrounds only the ducts. It is a single layer of 
epithelial cells. It does not line the lobules. 
• -They are contractile and aids the transport of secretion along the 
duct. 
The stroma:  
• fibrous stroma- suspensory ligaments of cooper 
• fatty stroma- the major part of the gland. 
Blood supply of the breast: 
 The breast is highly vascular. 
1. Medially- Internal thoracic artery-  a branch of subclavian artery 
2. Laterally- lateral thoracic, superior thoracic and acromiothoracic 
branches of the axillary artery 
3. Posterior intercostals arteries branches 
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The veins follow the arteries. 
Superficial veins- drain into the internal thoracic vein. 
The deep veins- to the internal thoracic, axillary and posterior intercostals 
veins. 
The communication of posterior intercostals veins with the Batson’s 
vertebral venous plexus is the basis of spread of breast malignancy to vertebra and 
skull base 
Nerve supply: 
 Anterior and lateral cutaneous branches of the 4th to 6th intercostals nerves.  
Sensory fibres- to skin 
Autonomic fibres- to blood vessels and smooth muscle. 
Lymphatic drainage of breast: 
 Lymph from the breast drains into the following nodes. 
1. Axillary nodes- defined by pectoralis minor muscle 
` Level 1 – lateral 
` Level 2 – posterior 
` Level 3 – medial 
a. Anterior or pectoral group 
b. Posterior or subscapular  group         level 1 
c. Lateral or humeral group 
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d. Central group                           -        level 2 
e. Apical group   - level 3 
2. Internal mammary  (parasternal nodes)- situated along internal thoracic 
vessels 
3. Interpectoral or rotters nodes- between pectoralis major and minor 
4. Some also reaches  
- the supraclavicular nodes 
- the cephalic(deltopectoral) nodes, 
- the posterior intercostals nodes 
- subdiaphragmatic and subperitoneal lymph plexuses. 
5. Few lymphatic pierce the pectoral fascia & enter the chest  
The lymphatics pass radially to the surrounding lymph nodes. The deep 
lymphatics drain the parenchyma of breast. They also drain the nipple and areola. 
1. About 75% of the lymph-into the axillary nodes 
 20% into the internal mammary nodes 
 5% into the posterior intercostal nodes. 
Among the axillary nodes, they mostly drain- into the anterior group partly 
into the posterior and apical group. 
2. The internal mammary nodes drain the lymph not only from the 
inner half of the breast but from the outer half as well. 
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3. A plexus of lymph vessels- subareolar plexus of Sappey, is 
present deep to the areola. 
4. The lymphatics from the deeper surface of the breast pass 
through the pectoralis major muscle and the clavipectoral fascia 
to reach the apical nodes and also to the internal mammary 
nodes. 
5. Lymphatics from the lower and inner quadrants of the breast  
 
crosses the costal margin and pierces the anterior abdominal wall 
through the upper part of linea alba. 
                           
communicate with the subdiaphragmatic and subperitoneal 
lymph   plexuses 
 
Aetiological factors: 
1.Geography : 
More common in the Western World 
2.Age: 
Rare below 20 years of age. 
 The incidence is more common after 40 years of age and keeps rising 
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3.Gender: 
 Females- most common 
<0.5% of patients- men 
4.Genetic: 
-Women with a family history of breast cancer 
- About 5% of breast cancers are related to specific mutations. 
5. Breast cancer syndrome: 
     i) Li-Fraumeni syndrome 
P53 gene mutation 
Autosomal dominant mutation 
      ii) Cowden’s disease 
Multiple hamartoma syndrome 
Facial trichilemmoma, papilloma, bilateral breast cancer 
iii) Ataxia telangiectasia 
Hemangioma breast cancer 
6.Chromosomal Abnormalities: 
i) BRCA one gene mutation – Chromosome 17q 
Poorly differentiated 
Invasive ductal type 
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Hormone receptor negative 
Associated with ovarian, prostate and colon cancers 
     ii) BRCA-2 gene mutation – Chromosome 13 q 
Well differentiated 
Invasive ductal carcinomas 
Express hormone receptors 
Associated with ovarian, colon, prostate, pancreas, gallbladder, bile 
duct, stomach cancers and melanoma 
      iii) HER-2 mutation (rbB2, transmembrane growth factor) 
Invasive breast cancer ; upto 80% ductal carcinoma 
Poor prognosis 
  iv) P 53 mutation 
Associated with poor prognosis   
Resistance to chemotherapy 
7. Diet: 
There is a causal association between breast cancer risk and diets low in 
phytooestrogens. 
Alcohol intake- increased risk of developing breast cancer. 
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8. Endocrine: 
- Common in nulliparous women 
- Protective factors-  
• breast feeding 
• first child at an early age 
• late menarche and early menopause. 
 In post menopausal age, it is more common among obese 
persons due to the conversion of steroids to estrogen in their 
body fat. 
 Exogenous hormones- such as oral contraceptive pill and 
HRT, their role is controversial. But the benefits of these 
treatments overcome the adverse effect of developing breast 
cancer 
 The relative risk (RR) is used to quantify the increase in the 
chances of developing breast cancer associated with the 
above risk factors. 
RR 2.0- indicates that she has two times more risk of developing breast 
cancer than the general population 
RR of 0.5- indicates 50% decrease in the risk. 
Basic pathology behind carcinoma breast is explained by Koreman’s 
hypothesis. Anovulatory cycles are more common when there is unopposed 
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estrogen with no progesterone that are usually present in early menarche and late 
menopause. Hyperprolactinemia is inhibited in early child birth. 
 
Clinical features: 
 Carcinoma breast usually presents as 
1. Painless hard Lump 
2. Nipple retraction- invasion into lactiferous ducts 
3. Nipple discharge  
4. Dimpling or puckering of skin- cooper’s ligament involvement.  
5. Peau d’orange- due to obstruction of dermal lymphatics, opening of 
sebaceous glands and hair follicles get buried in the edema giving rise 
to the orange peel appearance. 
6. Edema of the arm-  occurs due to axillary dissection and radiotherapy to 
axilla. It can also occur due to infiltration of the axilla by the tumor 
causing the arm to swell due to blockage of both lymphatic and venous 
flow. It can be painful due to the involvement of brachial plexus. 
Complication of the edema is infection and are at a higher risk. It requires 
vigorous treatment with antibiotics.  
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7. Cancer-en-cuirasse-  
It occurs due to tumor infiltration of the chest skin and appears like 
a armour of coat. 
It can occur in patients with-   
-local recurrence after mastectomy 
-irradiation to the chest wall. 
Treatment- palliative 
8. Lymphangiosarcoma- appears as multiple subcutaneous nodules in the 
limb. 
Poor prognosis 
Some respond to chemo or radiotherapy 
Interscapulothoracic forequarter amputation is other option 
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STAGING EVALUATION: 
`  - examination of the patient clinically 
- X ray of chest 
- C.T scan of chest   
- ultrasound abdomen 
- bone scan if necessary 
Staging of the tumor is essential to determine both the prognosis and 
treatment of the patient. 
A patient with systemic metastasis, is likely to benefit from systemic 
chemotherapy to combat the metastasis than with surgery for the local disease. 
Pathology: 
Breast cancer may arise from the  
- the duct system epithelium- most commonly 
- the lobular system of breast.  
It may be 
- in situ 
- invasive cancer 
 Insitu lesions are now more common due to the increased detection during 
screening programs. 
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The grading of the tumor according to the degree of differentiation of the 
tumor are: 
- well differentiated 
- moderately differentiated & 
- poorly differentiated 
 The three factors used for the numerical grading system are, 
- nuclear pleomorphism 
- tubule formation 
- mitotic rate 
With the increase in the use of molecular markers, much more information 
about an individual tumor will be routinely reported, such as the likelihood of 
metastasis of tumor and the susceptibility of the tumor to treatment regimen. 
Pathological classification: 
       INSITU            INVASIVE 
 
    Ductal  lobular    -   infiltrating ductal 
       -    Invasive lobular 
• Comedo      -    Ductal/lobular 
• Cribriform     -    mucinous/ colloid 
• Micropapillary     -    tubular 
• Papillary      -    medullary 
• Solid      -    papillary 
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Nomenclature: 
- Ductal carcinoma - most common variant 
- lobular carcinoma - in15% of cases. Subtypes are 
classical type- better prognosis 
pleomorphic type 
- mixed ductal and lobular 
Rare variants: 
- colloid type- abundant mucin production 
- medullary type- sheets of large cells with lymphocytic 
reaction 
- tubular type  
Invasive lobular variant – they are usually bilateral and multifocal/ 
multicentric. 
Inflammatory carcinoma: 
¾ Inflammatory carcinoma is a highly aggressive cancer and rare 
variant. 
¾ It presents as a painful, swollen breast, with erythema but no 
clinically palpable mass. 
 occlusion of the lymphatics in subdermis by the 
carcinoma cells. 
¾ It mimics breast abscess. 
¾ To confirm the diagnosis- biopsy- undifferentiated carcinoma cells.  
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¾ Treatment options - aggressive chemotherapy, radiotherapy with 
salvage surgery 
In situ carcinoma : 
¾ preinvasive cancer 
¾ No epithelial basement membrane breach 
¾ Now more common due to early mammographic screening. 
¾ Types  
¾ ductal (DCIS) 
¾ lobular (LCIS)  
Both are markers for the development of invasive cancer in the future 
-DCIS classified by the Van Nuys system. It includes 
• Age of patient 
• type 
• microcalcification +/- 
• margin extent 
• size 
Patients with a high score – radiotherapy is required after excision 
Low score - needs no further treatment after excision. 
Paget’s disease of the nipple: 
- It is the superficial manifestation of an underlying breast 
malignancy. 
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- It appears as eczematous lesion of the nipple and areola 
- The nipple gets finally destructed. 
- Microscopically- large, ovoid cells with abundant, clear cytoplasm 
in the Malpighian layer of the epidermis. 
Pathogenesis of Carcinoma Breast: 
   Prolonged estrogen exposure 
   Genetic mutations 
   Environmental factors 
   Gender, age 
 
 
 Mutations resulting in loss of p53, inhibition of apoptosis, cell cycle propogation 
 
Dysplasia 
 
Metaplasia 
 
Insitu carcinoma 
 
Invasive malignancy 
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Staging of carcinoma breast: TNM staging 
T stage: 
T1- tumor size <2cm 
 1a- 0.1- 0.5cm 
 1b-0.5- 1cm 
 1c- 1 -2 cm 
T2- size 2- 5cm 
T3- size >5cm 
T4- any size with 
 4a- fixed to chest wall 
 4b- fixed to skin 
 4c- both 4a and 4b 
 4d- inflammatory carcinoma of breast 
N stage: 
N0- no nodes 
N1- mobile ipsilateral axillary nodes 
N2-    N2a- ipsilateral axillary nodes fixed 
 N2b-ipsilateral internal mammary nodes without axillary nodes 
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N3- 
 N3a- ipsilateral infraclavicular nodes +/- axillary nodes 
 N3b-ipsilateral internal mammary and axillary nodes 
 N3c-ipsilateral supraclvicular nodes +/- axillary and internal mammary 
node 
M stage: 
M0- no metastasis 
M1- distant metastasis 
Prognosis of breast cancer: 
The best indicators for prognosis are  
• size of the tumor at presentation 
• status of the nodal involvement 
• invasive and metastatic potential. 
Prognostic factors defined include 
• grading of the tumor 
• receptor status 
• measures of proliferation of the tumor - S-phase fraction and thymidine 
labeling index 
• analysis of growth factor 
• measurement of oncogene or oncogene products  
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Role of estrogen in carcinoma breast: 
Estrogens play a major role in promoting the proliferation of both the 
normal and the neoplastic breast epithelium. Its role as breast carcinogens has 
been recently confirmed by epidemiological studies.[5] Their carcinogenic effects 
are believed to be due to three different hypothesis: 
1. Through their receptor-mediated hormonal activity it causes stimulation of 
cellular proliferation. 
2. Through  cytochrome P450-mediated metabolic activation it increases the 
mutation rates and thereby causes direct genotoxic effects 
3. induction of aneuploidy. 
How levels of estrogen are affected by lifestyle factors? 
Diet:  
Increase the risk of cancer by 
• Directly increasing the estrogen amount in blood or  
• indirectly by causing obesity. 
Obesity increases the cancer risk in postmenopausal women. 
Dietary phytoestrogens:  
Phytoestrogens are estrogens found in plant foods. 
A diet rich in phytoestrogens decreases the risk of breast cancer. 
  25 
 
They are weaker estrogens that bind to estrogen receptors and inhibits the 
binding of  human estrogens to the receptor, and thereby decreases the rate of 
division of breast cells.  
The menstrual cycles in women taking diet rich in phytoestrogens are 
longer and fewer. All these factors results in decreased risk of breast cancer. 
Body weight: Breast cancer risk increased by weight gain. In postmenopausal 
women, the ovaries stop producing estrogen and hence the primary source for 
estrogen in them is their body fat. Therefore women with higher levels of body fat 
in the postmenopausal period are expected to have a higher level of estrogens 
compared to a lean woman of their age. Trying to limit the increase in weight gain 
by eating healthy diet, and doing exercise reduce their risk of breast cancer . 
Exercise: Women doing exercise regularly have lower estrogen levels, due to 
decrease in the body fat, thereby decreasing the breast cancer risk. Exercise may 
also increase the duration of menstrual cycles and results in decreased exposure to 
estrogen. So younger women are advised to do regular exercise. 
Alcohol: Alcohol drinking increases the breast cancer risk, which is proportional 
to the amount of alcohol intake. Some theories suggest that estrogen levels 
increase due to alcohol consumption. 
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Birth control pills: Its association with breast cancer is controversial. It depends 
on the 
- estrogen quantity in the pill 
- the duration 
Postmenopausal hormone treatment: 
After menopause, estrogen production in the ovaries gets stopped. Estrogen 
loss increases the risk of  blood vessel and heart disease, osteoporosis and  
symptoms of discomfort. To minimise these adverse effects estrogen replacement 
treatment has been used. But the adverse effect of therapy is the risk for 
endometrial carcinoma is increased. Due to this increased cancer risk, 
progesterone, which counteracts this risk, was also added to the treatment 
regimen. In women who have had hysterectomy, estrogen alone regimen can be 
used. Recent trials analysed that the postmenopausal treatment result in an 
increases the breast carcinoma risk but is unlikely to prevent the heart and blood 
vessel disease. So, many health associations have now recommended to stop the 
usage of hormone replacement treatment for health promotion and for prevention 
purpose of most diseases. 
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Role of progesterone in ca breast: 
Progesterone is an steroid hormone from the ovary that is essential for the 
normal pubertal development of breast and also for the preparation for lactation 
and breastfeeding. Progesterone actions are mainly mediated by its high-affinity 
receptors, the progesterone receptors (PR)-A and -B isoforms. They are located in 
different tissues, such as the brain, where it controls reproductive behavior, and 
also located in the breast and reproductive organs. Progestins are usually used as 
contraceptive or in postmenopausal hormone replacement therapy, in which they 
are combined with estrogen inorder to counteract the estrogen-induced 
endometrial growth. The role of estrogen as a potent mitogen for breast is 
undoubted, and therefore the estrogen receptor inhibitors and the estrogen-
producing enzymes inhibitors(aromatases) are effective first-line therapies for 
breast cancer. However, PR action in breast cancer is understudied and it remains 
controversial.  
Role of her 2 neu: 
Over expression or gene amplification of the c-erbB-2/HER2/neu tyrosine 
kinase results in breast carcinoma of poor prognostic type. It manifests as increase 
in risk of metastasis, shorter disease-free intervals and refractory to treatment. 
 c-erbB-2 is activated by heterodimerization with other family members of 
the receptor family (EGFR, c-erbB-3, c-erbB-4). 
Its activation augments the motility of the tumor cell, secretion of protease 
and tumor invasion, and modulates the checkpoint function of cell cycle, 
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apoptotic responses and DNA repair. It is expressed at low levels normally, and 
therefore the treatment modality is targeted against c-erbB2.  
ESTROGEN RECEPTOR: 
 
 
Estrogen receptors are proteins found inside cells. They are activated by 
the hormone estrogen (17β-estradiol).  They occur as two different classes: 
1. ER- an intracellular receptor belonging to nuclear hormone family 
2. GPER (GPR30) – 
Here we discuss about the former ER type of receptor 
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Once activated by estrogen 
 
the ER translocates into nucleus 
 
bind to the DNA 
 
regulate activity of different genes. 
 
It also has additional functions independent of binding of DNA.  
There are two different forms of the estrogen receptor 
- ER α 
- ER β 
Encoded by genes 
ESR1 and ESR2 respectively. 
Hormone-activated estrogen receptors form dimers. 
o homodimers - ERα (αα) or ERβ (ββ) 
o heterodimers- ERαβ (αβ) 
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Genetics: 
The two forms of the estrogen receptor are encoded by 
ESR1gene -  on chromosome six 
ESR2 gene -  on chromosome fourteen 
Distribution:  
The ERα – 
 breast cancer cells 
 endometrium 
 ovarian stromal cells and  
hypothalamus. 
In males they are found in the efferent duct epithelium. 
The ERβ- ovarian granulosa cells, heart, lungs, prostate, intestinal mucosa, 
endothelial cells, kidney, brain and bone. 
The affinity differ with different ligands for binding to alpha and beta 
isoforms of the estrogen receptor  
Selective estrogen receptor modulators (SERMs) selectively bind to either 
alpha or beta subtype of the receptor, which then leads to agonistic and 
antagonistic effects at selective sites. 
The ratio of α- to β concentration is important in certain diseases. 
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The concept of  SERMs is based on the ability to initiate the interactions of 
estrogen receptors with the proteins such as   
• transcriptional coactivators 
• transcriptional corepressors. 
The ratio of coactivator to corepressor protein varies in different 
tissues. Therefore, the same ligand may be 
- agonist at some tissue (where the coactivators predominate)  
- antagonistic in other tissue (where the corepressors  
predominate). 
Tamoxifen, is an antagonist in breast but an ER agonist in bone  and is, therefore, 
used as a breast cancer treatment  and also prevent osteoporosis. But it increases 
the risk of endometrial cancer due to its partial agonistic action at endometrium. 
In around 70% of breast cancer cases, estrogen receptors are over-
expressed and they are referred to as "ER-positive". 
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Why this causes tumorigenesis, is explained by two hypotheses: 
Binding of estrogen to ER 
 
stimulates the proliferation of mammary cells 
 
increase in the cell division 
 
DNA replication 
 
leading to mutations. 
Estrogen metabolism 
 
Produces genotoxic waste 
 
mutations 
Both these processes 
 
Disruption of the cell cycle, apoptosis and DNA repair 
 
Tumor formation 
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Other cancers associated with estrogen and its receptor are  
-ovarian cancer 
-endometrial cancer 
-colon cancer 
-prostate cancer. 
The ERβ is the predominant ER in colon tissue. A loss of ERβ is associated 
with advanced colon cancer, and it is treated with ERβ-specific agonists. 
To assess the sensitivity of the  breast cancer lesions to hormonal treatment using 
tamoxifen and aromatase inhibitors, ER status is used. 
 However, some patients have de novo resistance to endocrine therapy. 
The ESR1 gene mutations are responsible for resistance. 
Mutations in the ligand binding domain of ESR1 
 
Constitutive  estrogen-independent activity 
 
Even in the absence of hormone stimulation tumor progression 
occurs 
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PROGESTERONE RECEPTOR: 
 
 
The progesterone receptor (also known as NR3C3) is a protein found 
inside cells belonging to nuclear receptor subfamily. It is activated by 
progesterone, a steroid hormone . 
PR is encoded by a single PGR gene on chromosome 11q22, It has two 
main forms 
- PR A 
- PR B 
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They differ in molecular weight. 
Progesterone is essential to activate the progesterone receptors. When there 
is no binding hormone, the carboxyl terminal of the receptor inhibits transcription. 
Binding to the hormone induces structural change in the receptor that removes the 
inhibitory action of the carboxyl terminal. Progesterone antagonists prevent the 
structural reconfiguration of the receptor. 
After progesterone interacts with its receptor, dimerization occurs and the 
Pg- PgR complex enters into the nucleus and then binds to DNA. 
It leads to transcription and then formation of mRNA that is translated 
by the ribosomes to produce proteins. 
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Her 2 neu (erbb2) receptors: 
 
 
ERBB2 a proto-oncogene 
located at the human chromosome 17 (17q12). 
The ErbB family consists of 4 membrane-bound receptor tyrosine kinases.  
The other members of this family are  
- epidermal growth factor receptor 
- erbB-3 
- erbB-4 
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All these four contain 
intracellular domain 
extracellular ligand binding domain 
a transmembrane domain 
HER2 can dimerise with any of the other three receptors. 
Dimerisation results in autophosphorylation of the tyrosine residues and 
initiates a variety of signaling pathways. It promotes cell proliferation and also 
opposes apoptosis. 
ERBB2 gene amplification occurs in nearly 15-30% cancers. It results in 
increased recurrence of the disease and poor prognosis.  
The estrogen, progesterone and the Her2 neu receptors are estimated from 
the tissue sample using immunohistochemistry technique.[6] 
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Immunohistochemistry: 
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Immunohistochemistry- By using the principle of antibodies binding 
specifically to antigens, detection of antigens in cells of a tissue. 
The procedure was developed by Dr. Albert Coons in 1941. 
In the diagnosis of abnormal cells, immunohistochemical staining is used. 
First the procedure involves proper collection of the tissue, then fixing it and then 
sectioning. Before sectioning it, to fix the tissue, Paraformaldehyde is used . 
The sample may require additional steps such as deparaffinization and 
antigen retrieval, to render the availability of epitopes for antibody binding, and it 
involves treating with heat or protease.  
The antibodies may also partially bind to nonspecific proteins sites. High 
background staining which masks the target antigen detection is caused by 
increased non-specific binding. In order to reduce the background staining, the 
samples are incubated with buffer. It blocks the reactive sites and thereby prevents 
the nonspecific binding of the primary or secondary antibodies to it. 
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The direct method-  
• single-step method 
• a labeled antibody reacting directly with the antigen.  
• Simple and rapid- as only one antibody used 
• the sensitivity is lower due to low signal amplification. However, 
this is used less frequently than the muti-step indirect method. 
 
In the indirect method- 
• Primary antibody (first layer) which is unlabelled, binds to the 
target antigen and a secondary antibody (second layer) reacting with 
primary antibody is used. 
• More sensitive than direct test because of high signal amplification, 
which is due to the binding to each primary antibody by several 
secondary antibodies.  
A second stain is often applied after immunohistochemical staining of the 
target antigen. 
Dyes available for IHC include: hematoxylin, Hoechst stain and DAPI. 
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Molecular classification of breast cancer: 
Research on patterns of gene expression has suggested newer ways to 
classify breast cancers based on the molecular gene expression.[1]  Based on these, 
the breast carcinoma is categorized into four groups 
¾ Luminal A 
¾ Luminal B 
¾ Her 2 
¾ Basal like 
 
Luminal A and luminal B types: estrogen receptor positive. These cancers 
express genes that are similar to normal cells. 
- Luminal A cancers - low grade, grow slowly, best prognosis 
- Luminal B cancers - grow faster, prognosis is not as good as    
Luminal A. 
 
HER2 type: They have additional copies of the HER2 gene. 
- high-grade appearance 
- tendency to grow more quickly 
- worse prognosis 
- treated with targeted therapies against HER2 
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Basal type:  
- Usually triple-negative type. 
- Estrogen and progesterone receptors deficient 
Normal HER2. 
- Similar to the cells in the basal layers of breast ducts and 
glands in their gene pattern. 
- BRCA1 gene mutations are mostly associated with this type 
of cancers. 
- This cancer is also more common among younger women. 
- They are high-grade cancers which grow quickly 
- have a poor prognosis 
- poor candidates for hormone therapy and anti-HER2 
therapies 
- Chemotherapy can be helpful. 
IHC predicts the response of breast cancer to hormonal therapy better. 
The Panel had recommended the cutoff to differentiate “positive” from 
“negative” cases as  ≥ 1% ER-positive tumor cells. 
It suggested  
• Considering endocrine therapy in patients showing at least 1% ER-
positive cells 
• withholding the endocrine therapy if it is less than 1%. 
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These recommendations will also result in a slight increase in the 
application of endocrine therapy. 
The stained tumor cells percentage provides predictive and prognostic 
information regarding the tumor. 
 Fewer studies have described “The relationship between hormone receptor 
levels and patient outcomes. Overall survival, disease-free survival, recurrence / 
relapse-free survival, 5-year survival, time to treatment failure, response to 
endocrine therapy, and time to recurrence were all positively associated with ER 
levels. Overall survival, time to treatment failure/progression, response to 
endocrine therapy, and time to recurrence were positively related to PR levels. 
These studies suggest that patients with higher hormone receptor levels will have 
a higher probability of positive outcomes and may influence oncologists' and 
patients’ treatment decisions.” 
While some other literature suggest that “the predictive role of PR may not 
be as important clinically as ER, other studies have shown that PR status provides 
additional predictive value independent of ER values, especially among 
premenopausal women.” 
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Reporting the results of IHC: 
Taking these into consideration, the Panel recommends that the ER and PR 
results shall be reported with  
3 required result elements 
2 optional result elements. 
 
The three required elements are: 
1. The percentage of tumor cells staining positive should be reported. 
In the tissue section on the slide, all the areas containing tumor should 
be evaluated to arrive this percentage. 
2. The staining intensity is measured and interpreted as 
 Weak 
 Moderate 
 Strong 
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It represents the average staining intensity of the positively stained 
tumor cells compared to positive controls. 
3. A measure of assay quality over time is used to provide the intensity 
The assay interpretation is based on: 
• Receptor positive: (either ER or PR)  
Atleast 1% or greater of tumor cells positive for ER/PR 
• Receptor negative:  
If the tumor cells that do stain positive for ER or PR, are only less than 
1% and of any intensity is considered negative and such patients do not benefit 
from endocrine therapy. 
Negative should be considered only in the presence of extrinsic and 
intrinsic controls which stain appropriately. 
If there are no intrinsic elements (normal breast epithelium) in the 
specimen and they show negative for receptor status, the assay should be 
repeated using another tumor specimen and then reported as uninterpretable. 
• Receptor uninterpretable: 
A result should be considered uninterpretable, 
o  If the preanalytic specifications of the guideline for sample is not 
followed 
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o  If the procedures used for processing the sample did not conform 
to the guideline specifications 
o  If the validated assay was not used for analyzing the specimen 
Examples of conditions resulting in uninterpretable results are:  
o Analyzing  the samples that are fixed in alcohol, or using 
fixatives other than 10% neutral buffered formalin 
o  biopsies that are  
 fixed for shorter intervals less than 6 hours  
 or for longer intervals more than 72 hours 
o fixation delayed more than 1 hour 
o Using strong acids for prior decalcification of the samples 
o Inappropriate staining of controls 
If the result is uninterpretable, then the reason for it should be 
mentioned, and an alternative good sample should be suggested for retesting, if 
appropriate. 
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Two optional report elements that are recommended by the Panel, but are not 
required are: 
1. A cautionary statement might be added to negative ER and PR, when the 
histopathology of the particular tumor is usually associated with ER-
positive and PR-positive results. 
These tumors include tubular, mucinous and lobular histologic types or 
those tumors with Nottingham score of 1. 
The cautionary statement must indicate that though the patient's tumor is 
tested as ER negative, tumors almost always test positive with 
Nottingham score 1 or tumors having similar histological type. 
2. Utilising the percentage and intensity measurements, the pathologist may  
provide a composite score such as the  
 H score 
 Allred score 
 Quick score 
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ER/PR scoring system and criteria: 
SCORING SYSTEM RECEPTOR STATUS CRITERIA 
0 Negative 0% nuclear staining 
1+ Borderline <10% nuclear staining 
2+ Positive 10 - 75% nuclear staining
3+ Positive >75% nuclear staining 
 
Her2 neu scoring system and criteria: 
SCORING SYSTEM RECEPTOR STATUS CRITERIA 
0 Negative 
No staining observed or 
membrane staining <10% 
of tumor  cells 
1+ Negative 
A faint/ barely 
perceptible staining 
detected in >10% of 
tumor cells 
2+ Weak positive 
Weak to moderate 
complete membrane 
staining in >10% of 
tumor cells 
3+ Positive 
A strong complete 
membrane staining in 
>10% of tumor cells 
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Receptor status in different etiologies of Breast cancer: 
Factors more consistently associated with increased risk of  ER positive 
tumors are: 
• Exposures related to reproduction  
• Nulliparity and late child birth 
• early menarche 
• Postmenopausal obesity- possibly reflecting the increased synthesis 
of estrogen in adipose tissue and greater bioavailability of it. 
The exogenous estrogen usage such as oral contraceptive pills or hormone 
replacement therapy, increasing the risk of hormone-sensitive tumors is not 
established. 
 Risk factors that do not differ by receptor status are: 
- breast-feeding 
- premenopausal obesity 
- cigarette smoking 
- alcohol consumption 
- family history of breast cancer 
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Methods to assess hormone receptors: 
1. Immunohistochemistry 
2. Flow cytometry 
3. Tissue microarray 
4. FISH (Fluorescent insitu hybridization) 
Advantages of immunohistochemistry : 
¾ Easily available  
¾ Inexpensive 
¾ Rapid results 
¾ Free of infectious agents so no human health risk 
¾ Good cell morphology reservation 
Limitations of immunohistochemistry: 
1. molecular genetics could not be simultaneously assayed as in flow 
cytometry. 
2. Fixatives used can affect some of the antibody binding sites making 
the interpretation difficult. 
3. Standardisation is very difficult. 
4. Difficult to quantitate. 
5. Success depends on antibody. 
6. Well trained pathologists are required. 
 
  51 
 
Treatment for Breast cancer: 
 It’s a multimodality approach including 
- Surgery 
- Chemotherapy- adjuvant/ neoadjuvant 
- Radiotherapy- to breast and axilla 
- Hormonal therapy and anti Her2neu antibody 
In this context, we discuss about the hormonal therapy pertaining to our 
topic, used in the management of breast cancer. 
 
Hormonal therapy for the treatment of Breast Carcinoma: 
Hormone therapy is a form of systemic therapy. 
- As an adjuvant therapy- to minimize the cancer recurrence 
- It can also be used as neoadjuvant treatment. 
- It is also used for treating recurrent tumors 
- Used for treating the metastatic spread of the tumors. 
Source of estrogen: 
- Before menopause- Ovaries 
- After menopause - the body's adipose tissue, where the 
adrenal androgens are converted to estrogen. 
In patients having receptor-positive tumors, estrogen accelerates the tumor 
growth. In breast cancer, about two - thirds are hormone receptor-positive. 
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 Most hormone therapy treatments for breast cancer act by  
- Decreasing the amount of estrogen or 
-  by preventing the action of estrogen on its receptor in the 
tumor cells 
This treatment is useful in patients positive for hormone receptors, but does 
not help the patients who are negative for hormone receptor. 
 
Drugs that block estrogen action: 
1. Tamoxifen:  
The estrogen receptors in breast cancer cells are blocked 
 
Estrogen binding to its receptors is prevented 
• anti-estrogen effect in breast cells 
 estrogen agonist effect in the uterus and bones. 
• Due to this property of differential action, the name- selective estrogen 
receptor modulator or SERM. 
` In breast cancer positive for hormone receptor - tamoxifen for five 
to ten years as adjuvant treatment after surgery. 
` It decreases the recurrence of malignancy. 
` New breast carcinoma risk in the contralateral breast is reduced. 
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` For early stage breast lesion, this drug is mainly used before the 
women attain menopause.  
` For women treated for ductal carcinoma in situ (DCIS), it reduces 
the chance of recurrence and its invasiveness. 
` It inhibits the growth and cause shrinkage of tumors in women with 
tumor metastatis. 
 
Side effects of SERM:  
Common side effects: 
1. Fatigue 
2. vaginal dryness or discharge 
3. hot flashes 
4. mood swings. 
5. "tumor flare"- in patients with metastasis to bones-  causing pain in the 
muscles and bones. 
Some of the serious and rare side effects are: 
1. Increased risk of developing endometrial cancer and uterine sarcoma in 
postmenopausal women. a common presentation of these side effects are 
vaginal bleeding. But most uterine bleeding is not due to malignancy, and 
this symptom always needs immediate attention. 
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2. Coagulopathy. It usually occur as deep venous thrombosis in the legs, but 
can also sometimes cause pulmonary embolism due to dislodge or break in 
the clot. Symptoms are pain, erythema, or swelling in calf muscles, 
dyspnea, chest pain or hemoptysis. 
3. Rarely, tamoxifen is associated with stroke in post-menopausal women 
which may present as severe headaches, confusion, or difficulty in 
speaking or moving. 
Tamoxifen has different effects on the bones depending on a woman's menopausal 
status, 
In pre-menopausal women- causes bone thinning 
In post-menopausal women- it prevents osteoporosis. 
The benefits outweigh the risks for almost all women taking these drugs. 
Dosage- 10 mg twice daily for a period of 5 years 
Toremifene: A SERM drug approved only to treat the metastatic breast cancer.  
Fulvestrant:  
¾ Estrogen receptor is blocked and then also temporarily eliminated. 
¾ Not a SERM  
¾ Estrogen antagonist action in all tissues in the body. 
¾ Fulvestrant is used to treat advanced or metastatic breast cancer. 
¾ It is administered as intramuscular injection in the gluteal region. 
¾ first month-  given in the dose of 2 weeks apart. 
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¾ Then once in a month.  
¾ Adverse effects - night sweats, hot flashes, fatigue and osteoporosis 
¾ Use- for treating advanced breast cancer in the post-menopausal women. 
¾ It can sometimes be suggested “off-label” in women before attaining 
menopause, along with LHRH agonist to turn off the ovaries. 
Raloxifene:  
It is also a SERM which has antiestrogenic action on both breast and 
endometrium and estrogen agonist in bones. So it has the advantage of no 
increased risk in endometrial cancer and also prevents osteoporosis.  
Dosage-  60 mg tablet once daily 
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Treatments causing decrease in the amount of estrogen: 
Aromatase inhibitors (AIs): 
Adrenal androgens 
      Aromatase   ×  (aromatase inhibitors) 
Estrogen 
• In post-menopausal women, these drugs prevent the production of 
estrogen and breast carcinoma in early and late stages can be treated 
using it. 
•  It includes 
- letrozole  
-  anastrozole 
- exemestane .  
• The aromatase enzyme in fat tissue is blocked.  
• The ovarian production of estrogen cannot be stopped, hence 
effective only in postmenopausal women who has no ovarian 
function, either 
- due to menopause 
- Or due to luteinizing hormone-releasing hormone analogs 
treatment. 
They are consumed as daily dosage pills.  
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The aromatase inhibitors to tamoxifen as adjuvant hormone therapy in 
post-menopausal women has been compared in many studies. 
The risk of the recurrence on using tamoxifen alone for five years is more than 
usage of AI drugs, either alone or after tamoxifen.  
Schedules that are helpful include: 
 Tamoxifen - two to three years, followed by an aromatase inhibitor  to 
complete the five years of treatment 
 Tamoxifen for 5 years, and then an AI for 5 years 
 An AI alone for 5 years 
For women with early breast cancer who are in pre menopausal age,  
o At first tamoxifen is used. 
o If they attain menopause during the treatment, then an AI may be 
administered later 
o Other choice is shutting down the ovaries by using drugs such as a 
LHRH analog along with an AI. 
Side effects- less serious than tamoxifen- no risk of endometrial cancer or 
coagulopathy. It causes muscle pain and joint stiffness. 
As aromatase inhibitors remove all the estrogens in post menopausal 
women , they can cause thinning of bones, which in turn leads to osteoporosis. 
To increase the bone strength, many women on aromatase inhibitor treatment are 
also given bisphosphonates or denosumab. 
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Ovarian ablation:  
The ovarian ablation in women before menopause , resulting in the woman 
to attain menopause. This allows the improved working of hormone therapies and 
is usually used to treat the breast carcinoma with metastasis. 
Permanent ovarian ablation done by surgical means- oophorectomy.  
Ovarian ablation can be done with drugs such as luteinizing hormone-
releasing hormone (LHRH) analogs, such as goserelin or leuprolide. These drugs 
act by blocking the signal sent from pituitary to the ovaries for estrogen synthesis. 
They can be used alone or along with other hormone drugs. 
 
Trastuzumab: 
It is a monoclonal antibody against the HER2/neu receptor.  The overall 
survival in HER2-positive patients with metastatic breast cancer is improved. The 
trastuzumab and chemotherapy combination increased both the survival and 
response rate, when comparing with treatment with trastuzumab alone. The exact 
duration of trastuzumab therapy required is currently unknown. One year duration 
is usually accepted. 
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Mechanism of action: 
 Trastuzumab acts by binding to the domain IV of the extracellular part of 
the HER2/neu receptor. It causes the cell cycle to arrest inG1 phase and so there is 
decreased proliferation. It is also suggested that trastuzumab exerts its effect 
by causing downregulation of the HER2/neu leading to disruption of dimerization 
of receptor and also the PI3K cascade signaling is reduced. By induction of 
antiangiogenic factors and suppression of proangiogenic factors it 
suppresses angiogenesis. 
 
Side effects: 
o flu-like symptoms, nausea and diarrhea 
o cardiotoxicity- it causes cardiac dysfunction in 2- 5% patients 
leading to congestive cardiac failure. Therefore routine echo should 
be done in patients receiving trastuzumab therapy. It occurs due to 
the downregulation of neuregulin-1 which activates the MAPK 
pathway and the PI3K/AKT pathway in cardiac myocytes and is 
essential for its survival. 
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Treatment for Triple negative Breast Cancer: 
 Triple -ve cancer has poor prognosis and are usually refractory to many 
therapies. Treatment involves multimodality approach such as surgery, 
radiotherapy, chemotherapy. 
 Some studies show that triple negative tumors respond better to 
chemotherapy when compared to receptor positive tumors. 
 But resistance to taxanes and anthracyclines based regimen do occur in 
them. For those, newer drugs are under evaluation such as 
1. Eribulin- microtubule inhibitor causing mitotic blockade 
2. Bevacizumab- antiangiogenesis 
3. Cetuximab- against epidermal growth factor 
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The study literature by Desombre and Jensen demonstrated  “ A decrease 
in the ER content as a tumor progresses. PR is a surrogate marker of functional 
ER because PR is an estrogen-regulated gene. More than half of ER+ tumors 
express PR. Hence, simultaneous analysis of ER and PR gives more information 
regarding likely hormonal response. Some studies have reported the presence of 
PR as a better predictive marker of response to hormone therapy than quantitative 
ER. Of breast carcinomas, 55% express both ER and PR, whereas 22% do not 
express either ER or PR. In addition, 20% of tumors are ER+ and PR–, and 3% 
are ER– and PR+.” 
 In another study conducted by Hussain Gadelkarim Ahmed, Mohammed 
Ali Al-Adhraei regarding correlation of ER,PR, Her2 and p53 status in Yemen 
women, it showed “The positive expression of different markers in all cases of 
ductal carcinoma: 60 (43.8%) positive for ER, 37 (27%) for PR, 42 (30.6) % for 
Her2/neu and 67 (48.9) % for p53. The P values of the overall expression of ER, 
PR, Her2/neu and P53 in cases compared with controls were 0.16, 0.01, 0.001 and 
0.0001.” 
            Fisher et al7 found “the presence of ER is significantly associated with 
high nuclear grade and low histologic grades, absence of tumor necrosis, presence 
of marked tumor elastosis and older patient age groups.” 
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            S. B. Desai et al study8 “ 798 breast carcinomas in Indian population and 
found 32.6% ER positive and 46.1% PR positive. ER, PR immunoreactivity 
increased with advancing age and correlated with presence of elastosis. 
Infiltrating lobular, mucinous and mixed tumors were more frequently ER, PR 
positive. High grade infiltrating duct carcinoma , pure comedo DCIS and 
medullary carcinomas were predominantly ER, PR negative. The presence of 
necrosis and lymphovascular invasion showed an inverse relationship with ER 
and PR reactivity.”   
            Lakmini K. B. Mudduwa9 “studied 151 breast carcinomas for ER , PR 
status by using quick score. Quick score for ER was 0 in 54.3% and for PR was 0 
in 51.7%. the Nottingham grade, the mitotic count and the Nottingham Prognostic 
Index had a significant inverse relationship with quick score for hormone receptor 
status.”   
            Onitilo et al study13  “1134 cases of invasive breast carcinomas, it was 
observed that cases with ER,PR positive and Her2 neu negative subtype were 
more likely be older, have early stage breast carcinoma, present with smaller 
tumor and have a well/moderately differentiated histological grade. They were 
less likely be lymphnode positive, have a lobular phenotype and be treated with 
chemotherapy.”   
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            Bhargava et al10 studied “cytological nuclear grading of breast carcinoma 
and its correlation with ER/PR expression in 30 cases of carcinoma breast. On 
correlating Robinson’s nuclear grading with ER and PR status there was 
significant correlation between ER, PR positivity and lower nuclear grades.” 
            Studies by Ruibal et al11 and Thike et al12 “showed an association of the 
histological tumor grade with the ER/PR content. A transition from lower to 
higher histological grades was accomplished by a decrease in ER/PR content.” 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Observation and Results 
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OBSERVATION AND RESULTS 
 
 
 
In this study, a total of 75 patients were studied starting from the age 
groups above 30. Most of them were between 40 and 50 years. Second most 
common was in younger age less than 40 years. 
Most of the patients came under the age group 40- 50 years about 29.33%. 
The least was in the 50- 60 years age of about 21.33% 
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In our study group, 42 patients had a tumor of size less than 5 cm which is 
about 56% of the whole group. 33 patients had a tumor greater than or equal to 
5cm in size which constitutes 44% of the study sample. 
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In this study which included breast cancers of different histological types 
and grade 
IDC I- 26 patients 
IDC II- 28 patients 
IDC III- 12 patients 
Medullary carcinoma- 4 
Invasive lobular carcinoma- 3 
Ductal carcinoma insitu- 2 
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Out of 75 patients, 52 patients (69.33%) were positive for estrogen receptor 
and 23 (30.66%) were negative. 
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39 patients (52%) were progesterone receptor positive and 36 (48%) were 
progesterone receptor negative. 
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Here 28 (37.33%) patients had Her2 receptor positive and 47 (62.66%) 
were negative. 
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In patients under 45 years of age (total 31), 23 patients (74.19%) were ER 
positive and 8 (25.81%) were negative. Above 45 years of age (total 44),                   
28 patients (63.63%) were ER positive and 16 (36.36%) were negative. 
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In estimation of PR receptors, under 45 years 23 patients (74.19%) were 
PR positive and 8 (25.81%) were negative. Above 45 years of age 28 (63.63%) 
patients were PR positive and 16 (36.36%) were negative. 
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<45 years-    12 patients (39%) positive    ;  19 (61%) negative 
>45 years-     15 patients (34%) positive   ;     29 (66%) negative 
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In tumors less than 5 cm in size 
 ER positive- 34 patients 
 ER negative- 8 patients 
 PR positive- 26 patients 
PR negative- 17 patients 
Her2 positive- 14 patients 
Her2 negative- 27 patients 
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In tumors more than or equal to 5 cm in size 
 ER positive- 18 patients 
 ER negative- 15 patients 
 PR positive- 12 patients 
PR negative- 20 patients 
Her2 positive- 15 patients 
Her2 negative- 19 patients 
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Summary 
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SUMMARY 
 
 Breast cancer is one of the most common cancers among women of all age 
groups. In recent years the there is an increase in the incidence of breast cancer 
due to the lifestyle modifications, and increase in screening programs which help 
to detect them at an early stage. Breast cancer treatment involves a 
multidisciplinary approach. Hormone therapy is one among the treatment 
modality. Estrogen, progesterone and Her2 neu receptor status estimation is very 
crucial at present in order to predict the tumor response to the hormonal therapy 
and also to assess the prognosis of the cancer. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Conclusion 
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CONCLUSION 
 
 In my study a total of 75 female patients with breast cancer in my institute 
were studied. the incidence of ER, PR, Her2 neu receptors among them 
correlating with age, tumor size, histological type and the pathological grading 
was evaluated. 52 patients (69.33%) were positive for estrogen receptor and 23 
(30.66%)  were negative. 39 patients (52%) were progesterone receptor positive 
and 36 (48%) were progesterone receptor negative. 28 (37.33%) patients had Her 
2 receptor positive and 47 (62.66%) were negative. 
 Most of the tumors in women above45 years of age were hormone receptor 
positive. In women younger than 45 years both positive and negative were nearly 
equal. Similar results were observed in tumors less than 5cm where positivity 
predominated and more than 5 cm where both positive and negative were utmost 
equal. Her 2 was more negative in most of the patients of our study irrespective of 
age and tumor size. 
   These results were comparable with the previous studies and thus reinforce 
the usefulness of estimation of the receptor status for treatment purpose in breast 
carcinoma. 
 All patients with hormone receptor positivity were started with tamoxifen 
10 mg bd for a total duration of 5 years and their compliance is good till date with 
minimal side effects. 
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ANNEXURE I 
PHOTOS 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Trucut Biopsy Needle 
 
Estrogen receptor positive  
 
 
 
 
   
 
ANNEXURE II  
PROFORMA 
 
1. Name: 
2. Age: 
3. Sex: 
4. Inpatient no: 
5. Duration of illness: 
6. Size of tumor: 
7. Specimen: trucut biopsy/ mastectomy 
8. FNAC / Biopsy report: 
9. Grade of the tumor: 
10. Estrogen receptor: 
11. Progesterone receptor: 
12.  Her2 neu receptor: 
  
   
 
ANNEXURE III 
CONSENT FORM 
 
 I exercising my free power of choice, hereby give my full free and 
voluntary consent for myself to be a subject of the study “Clinical study of 
hormone receptor status in carcinoma breast”. 
 I have been informed to my satisfaction by attending surgeon Dr. 
………… the purpose of the study, the clinical and pathological investigations 
that are to be carried out and the nature and consequences of the surgery, 
anaesthesia and the likely complications in my own language. 
 I am aware of my right to not to opt for this study without having to give 
reasons for doing so. 
 
 
 
Signature of the surgeon:`    Signature of the patient: 
Date:       Date: 
 
 
 
 
 
 
   
 
ANNEXURE IV 
MASTER CHART 
SL.
No 
Name Age Sex 
Tumor 
Size 
(in cm) 
Pathological Grading 
ER 
Status 
PR 
Status 
Her 2 
Status
1 Chinnathai 70 F 3 * 3* 2  IDC NOS TYPE II -ve 1+ +ve 
2 Annaselvi 65 F 5 * 3 * 3 IDC NOS TYPE I 2+ -ve 1+ve 
3 Mariammal 35 F 4* 2 * 3 IDC  NOS type I 3 + 2+ -ve 
4 Mydeenmeeral 53 F 5 * 2 * 2  IDC  NOS type grade II -ve -ve -ve 
5 Ulagamayee 42 F 6 * 3 * 4 IDC  medullary type -ve -ve -ve 
6 Mariammal 40 F 4 * 3 * 1  IDC NOS TYPE II + + -ve 
7 Valliammal 65 F 7 * 4 * 2 IDC NOS TYPE III -ve + -ve 
8 Puthiyal 65 F 6 * 5 * 2  IDC NOS TYPE III -ve -ve -ve 
9 Natchiyar 60 F 4 * 4 * 3 IDC NOS TYPE II -ve -ve -ve 
10 Latha 39 F 2 * 2 * 1  Pagets disease 2 + -ve -ve 
11 Annalakshmi 58 F 4 * 3 * 2 
IDC NOS TYPE I 
ductal carcinoma insitu 
4 + 2 + -ve 
12 Thangammal 70 F 7 * 4 * 3 
IDC NOS TYPE I 
ductal carcinoma insitu 
4 + 2 + -ve 
13 Annal 62 F 6 * 4 * 2  IDC NOS TYPE II -ve -ve 2+ 
14 Shanthi 36 F 4 * 4 * 2 IDC NOS TYPE II 2 + -ve -ve 
15 Mariammal 40 F 3 * 3 * 2 IDC NOS TYPE II 2 + -ve 1+ve 
16 Shyamala 39 F 4 *3 * 2 IDC NOS TYPE III -ve -ve -ve 
17 Lakshmi 35 F 2 * 2 * 1 IDC NOS TYPE I 1+ 1+ 1+ 
18 Sudha 48 F 5 * 4 * 2 IDC NOS TYPE II -ve -ve 1+ 
19 Vijayalakshmi 45 F 4 * 2 * 2  IDC NOS TYPE I 2+ + 1+ 
20 Mallika 40 F 4 * 3 * 2 IDC NOS TYPE I 3 + 3 + -ve 
21 Latha 41 F 2 * 1 * 1 IDC NOS TYPE II -ve -ve -ve 
22 Rasammal 49 F 5 * 3 * 2 IDC NOS TYPE II 3 + 3 + -ve 
23 Chellamal 63 F 6 * 3 * 3 IDC NOS TYPE III -ve -ve 1+ 
24 Thamaraiselvi 48 F 5 * 3 * 2 IDC NOS TYPE II 1 + 2 + 2+ 
   
 
SL.
No 
Name Age Sex 
Tumor 
Size 
(in cm) 
Pathological Grading 
ER 
Status 
PR 
Status 
Her 2 
Status
25 Rasool beevi 70 F 7 * 4 * 2 IDC NOS TYPE I 2+ 1+ 1+ 
26 Piramu 59 F 6 * 3 * 2 IDC NOS TYPE I 4 + 3 + -ve 
27 Masanam 31 F 2 * 1 * 2 IDC NOS TYPE II 3 + -ve -ve 
28 Leelavathy 36 F 3 * 2 * 2 IDC NOS TYPE I 4 + 3 + -ve 
29 Natchiyar 60 F 4 * 4 * 1 IDC NOS TYPE I 2 + 3 + -ve 
30 Maideen Nisha 45 F 4 * 2 * 3 IDC NOS TYPE III -ve -ve 4+ 
31 Ponselvi 53 F 3 * 2 * 2 
IDC with 
comedocarcinoma 
2 + -ve 3+ 
32 Lakshmi 35 F 5 * 3 * 3 IDC NOS TYPE II 2 + -ve -ve 
33 Esakkiammal 47 F 3 * 3 * 3 IDC NOS TYPE III -ve -ve 2+ 
34 Valliamal 60 F 4 * 2 * 3 IDC NOS TYPE II 2 + -ve 2+ 
35 Gandhimathi 80 F 7 * 5 * 2 
IDC with mucinous 
areas 
2 + -ve 3+ 
36 Subbulakshmi 52 F 4 * 2 * 2 IDC NOS TYPE I 2 + -ve 2+ 
37 Maharaj 53 F 5 * 3 * 3 IDC NOS TYPE II -ve -ve -ve 
38 Ramalatha 64 F 6 * 3 * 3 IDC NOS TYPE II -ve -ve 1+ 
39 Murugathal 58 F 4 * 2 * 1 
Invasive lobular 
carcinoma 
3 + 3 + 
-ve 
 
40 Esakkiammal 47 F 5 * 3 * 3 IDC NOS TYPE I 2+ 2+ -ve 
41 Muthulakshmi 47 F 2 * 2 * 1 
IDC atypical medullary 
type 
4 + 2 + -ve 
42 Mariammal 35 F 3 * 1 * 1 IDC NOS TYPE II 2 + -ve 3 + 
43 Ponselvi 45 F 4 * 2 * 1 
IDC with 
comedocarcinoma 
2+ 1+ -ve 
44 Chandra 45 F 5 * 3 * 3 IDC NOS TYPE II 2 + -ve -ve 
45 Papa 55 F 7 * 4 * 3 IDC NOS TYPE I 2 + 2 + -ve 
46 Iyyammal 45 F 5  * 3 * 1 IDC NOS TYPE III -ve -ve + 
47 Meharaj 83 F 4 * 4 * 2 IDC NOS TYPE I 3 + 3 + -ve 
48 Annakaamal 65 F 3 * 4 * 2 IDC NOS TYPE III -ve -ve -ve 
   
 
SL.
No 
Name Age Sex 
Tumor 
Size 
(in cm) 
Pathological Grading 
ER 
Status 
PR 
Status 
Her 2 
Status
49 Bhuvaneshwari 32 F 5 * 5 * 2 IDC NOS TYPE II 2 + -ve 2 + 
50 Rajalakshmi 43 F 2 * 2 * 1 IDC NOS TYPE III 2 + -ve 2 + 
51 Chellathai 62 F 4 * 2 * 2 IDC NOS TYPE I 1 + -ve -ve 
52 Sundari 60 F 3 * 2 * 2 IDC NOS TYPE I 3 + 3 + 1 + 
53 Chinnathai 65 F 6 * 4 * 3 IDC NOS TYPE II -ve 1 + -ve 
54 Pushpam 38 F 3 * 2 * 2 IDC NOS TYPE I 2 + 3 + -ve 
55 Ramu 37 F 4 * 2 * 2 IDC NOS TYPE II +  + + 
56 Jebam ani 46 F 3 * 2 * 1 IDC NOS TYPE I 2 + 1 + -ve 
 F 4 * 3 *2 IDC NOS TYPE II 2 + 1 + -ve 
58 Ramu 45 F 2 * 1 * 1 IDC NOS TYPE I 3 + 2 + + 
59 Marthal 54 F 3 * 3 * 1 IDC NOS TYPE II 3 + 3 + -ve 
60 Rani 44 F 6 * 4 * 2 
Ductal/ lobular 
carcinoma 
-ve -ve -ve 
61 Esakiammal 27 F 5 * 3 * 2 IDC NOS TYPE II 1 + -ve -ve 
62 Sundari 47 F 4 * 4 * 1 IDC  cribriform + + -ve 
63 Rathinam 70 F 6 * 4 * 2 
IDC NOS TYPE  III 
with DCIS 
-ve -ve -ve 
64 Raajam 61 F 7 * 5 * 2 
IDC with medullary 
type 
-ve -ve -ve 
65 Gandhimathi 31 F 5 * 2 * 1 IDC NOS TYPE II 2 + -ve -ve 
66 Maheshwari 48 F 4* 3* 3 IDC NOS TYPE II 1+ 1+ -ve 
67 Annalakshmi 63 F 6* 4* 2  IDC NOS TYPE III -ve -ve 1+ 
68 Kanagavalli 52 F 3* 3* 2 Ductal carcinoma insitu 2+ 3+ -ve 
69 Alagammal 37 F 5 * 2 * 2 
IDC with medullary 
type 
1+ 1+ 1+ 
70 Ganga 57 F 4 * 2 * 2 
Invasive lobular 
Carcinoma 
2+ 2+ -ve 
71 Natchiyar 66 F 3 * 2 * 2 IDC NOS TYPE I 2+ 1+ -ve 
72 Amuthavalli 39 F 4 * 3 * 2 IDC NOS TYPE III -ve 1+ 1+ 
   
 
SL.
No 
Name Age Sex 
Tumor 
Size 
(in cm) 
Pathological Grading 
ER 
Status 
PR 
Status 
Her 2 
Status
73 Mariyam 49 F 6 * 3 * 3 Ductal carcinoma insitu 3+ 2+ -ve 
74 Mydeen beevi 54 F 5 * 3 * 2  IDC  NOS TYPE II 2+ 2+ 1+ 
75 Karpagam 45 F 5 * 4 * 3 IDC NOS TYPE II 1+ 1+ -ve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
ANNEXURE V 
KEY TO MASTER CHART 
 
ER  – estrogen receptor 
PR  –  progesterone receptor 
HER2  –  human epidermal growth factor receptor 
+ve  – positive 
-ve  –  negative 
IDC – invasive ductal carcinoma 
DCIS –  ductal carcinoma insitu 
NOS – no other specified type 
 
 
